Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Valerie Caterinicchia"'
Autor:
Erica M. Stringer-Reasor, Jori E. May, Eva Olariu, Valerie Caterinicchia, Yufeng Li, Dongquan Chen, Deborah L. Della Manna, Gabrielle B. Rocque, Christos Vaklavas, Carla I. Falkson, Lisle M. Nabell, Edward P. Acosta, Andres Forero-Torres, Eddy S. Yang
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-12 (2021)
Abstract Background Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of tri
Externí odkaz:
https://doaj.org/article/73538d58c45c449bae948e795b13f120
Autor:
Edward P. Acosta, Jori E. May, Lisle Nabell, Eva Olariu, Andres Forero-Torres, Erica Stringer-Reasor, Dongquan Chen, Eddy S. Yang, Valerie Caterinicchia, Gabrielle B. Rocque, Carla I. Falkson, Christos Vaklavas, Deborah L. Della Manna, Yufeng Li
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-12 (2021)
Breast Cancer Research : BCR
Breast Cancer Research : BCR
Background Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple-negat
Autor:
Erica M. Stringer-Reasor, Jori E. May, Eva Olariu, Valerie Caterinicchia, Yufeng Li, Deborah L. Della Manna, Gabrielle B. Rocque, Christos Vaklavas, Carla I. Falkson, Lisle M. Nabell, Edward P. Acosta, Andres Forero-Torres, Eddy S. Yang
Background: Poly (ADP-ribose)-polymerase inhibitors (PARPi) have been approved for cancer patients with germline BRCA1/2 (g BRCA1/2 ) mutations, and efforts to expand the utility of PARPi beyond BRCA1/2 are ongoing. In preclinical models of triple ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f33d8ade93192c27c40fc46394ecda0c
https://doi.org/10.21203/rs.3.rs-60551/v1
https://doi.org/10.21203/rs.3.rs-60551/v1
Autor:
Helen Krontiras, Andres Forero, Carla I. Falkson, Richard M. Myers, Lisle Nabell, K Bowen, Katherine E. Varley, Valerie Caterinicchia, John T. Carpenter, J DeLos Santos, Albert F. LoBuglio, Janis P. O'Malley, C. Jones, Mansoor N. Saleh, Y. Li
Publikováno v:
Cancer Research. 73:P1-15
Introduction: Vascular endothelial growth factor overexpression has been associated with resistance to anti-estrogen therapy (Cancer Res 2008; 68: 6232); our preclinical data showed that anti-VEGF therapy reverse resistance to estrogen therapy. We po
Autor:
Helen Krontiras, Andres Forero, Ruby F. Meredith, Mansoor N. Saleh, Lisle Nabell, Albert F. LoBuglio, Marshall M. Urist, W K Bernreuter, Carla I. Falkson, J.F. De Los Santos, Kirby I. Bland, Valerie Caterinicchia, Janis P. O'Malley, C. Jones, L Yufeng, J. Galleshaw, John T. Carpenter
Publikováno v:
Cancer Research. 70:P1-12
Introduction: Overexpression of vascular endothelial growth factor (VEGF) in breast cancer tumors has been associated with resistance to anti-estrogen adjuvant therapy. We designed a pilot study of neoadjuvant letrozole and bevacizumab (anti-VEGF) to
Autor:
Andres Forero-Torres, Janice A. Galleshaw, Janis P. O'Malley, Valerie Caterinicchia, Lisle Nabell, Jatin J. Shah, Kirby I. Bland, Mansoor N. Saleh, Marshall M. Urist, Yufeng Li, I. Percent, Carla I. Falkson, Jennifer F. De Los Santos, Cheryl F. Jones, Albert F. LoBuglio, Ruby F. Meredith, John T. Carpenter, W K Bernreuter, Helen Krontiras
Publikováno v:
Clinical Breast Cancer. 10:275-280
Introduction Tumor content or expression of vascular endothelial growth factor (VEGF) is associated with impaired efficacy of antiestrogen adjuvant therapy. We designed a pilot study to assess the feasibility and short-term efficacy of neoadjuvant le
Autor:
J.F. De Los Santos, Ruby F. Meredith, W K Bernreuter, John T. Carpenter, J. Galleshaw, Helen Krontiras, Andres Forero, Mansoor N. Saleh, Janis P. O'Malley, C. Jones, Valerie Caterinicchia, Carla I. Falkson, Jatin J. Shah, Lisle Nabell, Marshall M. Urist, I. Percent, Kirby I. Bland, Yufeng Li, Albert F. LoBuglio
Publikováno v:
Cancer Research. 69:1088-1088
Purpose Tumor content or expression of vascular endothelial growth factor (VEGF) is associated with impaired efficacy of anti-estrogen adjuvant therapy. We designed a pilot study of neoadjuvant letrozole and bevacizumab (anti-VEGF) to assess feasibil